Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naive Inflammatory Bowel Disease Patients: Results from the EVOLVE Study

Background and Aims: This study aimed to compare real-world clinical effectiveness and safety of vedolizumab, an alpha 4 beta 7-integrin inhibitor, and anti-tumour necrosis factor-alpha [anti-TNF alpha] agents in biologic-naive ulcerative colitis [UC] and Crohn's disease [CD] patients. Methods: This was a 24-month retrospective medical chart study in adult UC and CD patients treated with vedolizumab or anti-TNF alpha in Canada, Greece and the USA. Inverse probability weighting was used to account for differences between groups. Primary outcomes were cumulative rates of clinical effectiveness [clinical response, clinical remission, mucosal healing] and incidence rates of serious adverse events [SAEs] and serious infections [SIs]. Secondary outcomes included cumulative rates of treatment persistence [patients who did not discontinue index treatment during follow-up] and dose escalation and incidence rates of disease exacerbations and disease-related surgeries. Adjusted analyses were performed using inverse probability weighting. Results: A total of 1095 patients [604 UC, 491 CD] were included. By 24 months, rates of clinical effectiveness were similar between groups, but incidence rates of SAEs (hazard ratio [HR] = 0.42 [0.28-0.62]) and SIs (HR = 0.40 [0.19-0.85]) were significantly lower in vedolizumab vs anti-TNF alpha patients. Rates of treatment persistence [p < 0.01] by 24 months were higher in vedolizumab patients with UC. Incidence rates of disease exacerbations were lower in vedolizumab patients with UC (HR = 0.58 [0.45-0.76]). Other outcomes did not significantly differ between groups. Conclusion: In this real-world setting, first-line biologic therapy in biologic-naive patients with UC and CD demonstrated that vedolizumab and anti-TNF alpha treatments were equally effective at controlling disease symptoms, but vedolizumab has a more favourable safety profile.

Automated summary

The study compared the real-world clinical effectiveness and safety of vedolizumab and anti-TNF alpha agents in biologic-naive UC and CD patients. Results showed both treatments were equally effective at controlling disease symptoms, but vedolizumab had a more favorable safety profile.